Systemic Lupus Erythematous SLE Drugs Market Segments and Forecast By End-use Industry 2015-2025
Future Market Insights has announced the addition of the “Systemic Lupus Erythematous SLE Drugs Market: Global Industry Analysis and Opportunity Assessment 2015-2025” report to their offering.
Future Market Insights has announced the addition of the “Systemic Lupus Erythematous SLE Drugs Market: Global Industry Analysis and Opportunity Assessment 2015-2025” report to their offering.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Report Description<br />
Recently, a drug called belimumab has been approved by FDA after 50 years long gap specifically<br />
for <strong>SLE</strong> on March 9, 2011. It is the first ever targeted biological drug for the treatment of <strong>SLE</strong><br />
patients developed by Human Genome Sciences Inc. in collaboration with GlaxoSmithKline. It<br />
will be the primary driver for global systemic lupus erythematous drugs market growth in the<br />
US, France, Germany, Italy Spain, the UK <strong>and</strong> Japan. Benlysta will lead market sales in coming<br />
years beca<strong>use</strong> of its excellent safety profile as well as proven efficacy in clinical trials. NSAIDS<br />
such as Ibuprofen <strong>and</strong> aspirin are widely prescribed drugs for suppressing symptoms of <strong>SLE</strong>.<br />
Immunosuppressants by Roche (CellCept (Mycophenolate mofetil), by Novartis (Neoral<br />
(Cyclosporine)), by GSK (Imuran (Azathioprine)) are also commonly prescribed for <strong>SLE</strong><br />
treatment. Additionally, the entry of four first-in-class (FIC) biologics such as Bristol-Myers<br />
Squibb’s Orencia (abatacept), atacicept, epratuzumab <strong>and</strong> LY2127399 are anticipated to show a<br />
major role in the expansion of the global systemic lupus erythematous drugs market.<br />
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1149<br />
<strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) <strong>Drugs</strong> <strong>Market</strong>: Key Players<br />
The global systemic lupus erythematous drugs market key players are Anthera<br />
Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics,<br />
Johnson <strong>and</strong> Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.
Change language